Medscape www.medscape.com

References for:
Joint British Association of Dermatologists and U.K. Cutaneous Lymphoma Group Guidelines for the Management of Primary Cutaneous T-Cell Lymphomas

[Br J Dermatol 149(6):1095-1107, 2003. © 2003 Blackwell Publishing]

  1. Willemze R, Kerl H, Sterry W et al. EORTC classification for primary cutaneous lymphomas: a proposal from the cutaneous lymphoma study group of the European Organisation for Research and Treatment of Cancer. Blood 1997; 90: 354-71.
  2. Harris NL, Jaffe ES, Diebold J et al. The World Health Organization classification of neoplastic diseases of the haematopoietic and lymphoid tissues: report of the clinical advisory committee meeting, Airlie House, Virginia, November 1997. Histopathology 2000; 36: 69-86.
  3. Zackheim HS, Amin S, Kashani-Sabet M, McMillan A. Prognosis in cutaneous T-cell lymphoma by skin stage: long term survival in 489 patients. J Am Acad Dermatol 1999; 40: 418-25.
  4. Van Doorn R, van Haselan CW, van Voorst Vader P et al. Mycosis fungoides: disease evolution and prognosis of 309 Dutch patients. Arch Dermatol 2000; 136: 504-10.
  5. Kim YH, Jensen RA, Watanabe GI et al. Clinical stage IA (limited patch and plaque) mycosis fungoides. Arch Dermatol 1996; 132: 1309-13.
  6. Kim YH, Chow S, Varghese A, Hoppe RT. Clinical characteristics and long-term outcome of patients with generalized patch and/or plaque (T2) mycosis fungoides. Arch Dermatol 1999; 135: 26-32.
  7. de Coninck EC, Kim YH, Varghese A, Hoppe RT. Clinical characteristics and outcome of patients with extracutaneous mycosis fungoides. J Clin Oncol 2001; 19: 779-84.
  8. Kim YH, Bishop K, Varghese A, Hoppe RT. Prognostic factors in erythrodermic mycosis fungoides and the Sézary syndrome. Arch Dermatol 1995; 131: 1003-8.
  9. Kaye FJ, Bunn PA Jr, Steinberg SM et al. A randomized trial comparing combination electron beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N Engl J Med 1989; 321: 1748-90.
  10. Whittaker SJ. Primary cutaneous T-cell lymphomas. In: Evidence-based Oncology (Williams H, Bigby M, Diepgen T et al., eds). London: BMJ Books, 2003; IX: 498-517.
  11. Fraser-Andrews E, Woolford A, Russell Jones R, Whittaker SJ. Detection of a peripheral blood T-cell clone is an independent prognostic marker in mycosis fungoides. J Invest Dermatol 2000; 114: 117-21.
  12. Scarisbrick JJ, Whittaker SJ, Evans A et al. Prognostic significance of tumour burden in the blood of patients with erythrodermic primary cutaneous T-cell lymphoma. Blood 2001; 97: 624-30.
  13. Zackheim H, Kashani-Sabet M, Amin S. Topical corticosteroids for mycosis fungoides. Arch Dermatol 1998; 134: 949-54.
  14. Hoppe RT, Abel EA, Deneau DG, Price NM. Mycosis fungoides: management with topical nitrogen mustard. J Clin Oncol 1987; 5: 1796-803.
  15. Ramsey DL, Halperin PS, Zeleniuch-Jacquotte A. Topical mechlorethamine therapy for early stage mycosis fungoides. J Am Acad Dermatol 1988; 19: 684-91.
  16. Vonderheid EC, Tan ET, Kantor AF et al. Long term efficacy, curative potential and carcinogenicity of topical mechlorethamine chemotherapy in cutaneous T-cell lymphoma. J Am Acad Dermatol 1989; 20: 416-28.
  17. Zackheim H, Epstein E, Crain W. Topical carmustine (BCNU) for cutaneous T-cell lymphoma: a 15-year experience in 143 patients. J Am Acad Dermatol 1990; 22: 802-10.
  18. Breneman D, Duvic M, Kuzel T et al. Phase I and II trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma. Arch Dermatol 2002; 138: 325-32.
  19. Duvic M, Olsen E, Omura G et al. A phase III, randomized, double-blind, placebo-controlled study of peldesine (BCX-34) cream as topical therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol 2001; 44: 940-7.
  20. Hermann JJ, Roenigk HH Jr, Hurria A et al. Treatment of mycosis fungoides with photochemotherapy (PUVA): long term follow-up. J Am Acad Dermatol 1995; 33: 234-42.
  21. Roenigk HH Jr, Kuzel TM, Skoutelis AP et al. Photochemotherapy alone or combined with interferon alfa in the treatment of cutaneous T-cell lymphoma. J Invest Dermatol 1990; 95 (Suppl.6): 198-205.
  22. Honigsmann H, Brenner W, Rauschmeier W et al. Photochemotherapy for cutaneous T cell lymphoma. J Am Acad Dermatol 1984; 10: 238-45.
  23. Ramsey DL, Lish KM, Yalowitz CB, Soter NA. Ultraviolet-B phototherapy for early stage cutaneous T-cell lymphoma. Arch Dermatol 1992; 128: 931-3.
  24. Clark C, Dawe RS, Evans AT et al. Narrowband TL-01 phototherapy for patch stage mycosis fungoides. Arch Dermatol 2000; 136: 748-52.
  25. Zane C, Leali C, Airo P et al. 'High dose' UVA1 therapy of widespread plaque-type, nodular and erythrodermic mycosis fungoides. J Am Acad Dermatol 2001; 44: 629-33.
  26. Cotter GW, Baglan RJ, Wasserman TH, Mill W. Palliative radiation treatment of cutaneous mycosis fungoides: a dose response. Int J Radiat Oncol Biol Phys 1983; 9: 1477-80.
  27. Jones GW, Hoppe RT, Glatstein E. Electron beam treatment for cutaneous T-cell lymphoma. Haematol Oncol Clin North Am 1995; 9: 1057-76.
  28. Jones GW, Rosenthal D, Wilson LD. Total skin electron beam radiation for patients with erythrodermic cutaneous T-cell lymphoma (mycosis fungoides and the Sézary syndrome). Cancer 1999; 85: 1985-95.
  29. Hamminga B, Van Noordijk EM, Vloten WA. Treatment of mycosis fungoides: total skin electron beam irradiation vs topical mechlorethamine therapy. Arch Dermatol 1982; 118: 150-3.
  30. Becker M, Hoppe RT, Knox SJ. Multiple courses of high dose total skin electron beam therapy in the management of mycosis fungoides. Int J Radiat Oncol Biol Phys 1995; 30: 1445-9.
  31. Wilson L, Quiros PA, Kolenik SA et al. Additional courses of total skin electron beam therapy in the treatment of patients with recurrent cutaneous T-cell lymphoma. J Am Acad Dermatol 1996; 35: 69-73.
  32. Jones GW, Kacinski BM, Wilson LD et al. Total skin electron beam radiation in the management of mycosis fungoides: consensus of the European Organisation for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Project Group. J Am Acad Dermatol 2002; 47: 364-70.
  33. Bunn PA Jr, Ihde DC, Foon KA. The role of recombinant interferon alpha-2a in the therapy of cutaneous T-cell lymphomas. Cancer 1986; 57: 1689-95.
  34. Olsen EA, Rosen ST, Vollmer RT et al. Interferon alfa-2a in the treatment of cutaneous T-cell lymphoma. J Am Acad Dermatol 1989; 20: 395-407.
  35. Papa G, Tura S, Mandelli F et al. Is interferon alpha in cutaneous T-cell lymphoma a treatment of choice? Br J Haematol 1991; 79: 48-51.
  36. Dreno B, Claudy A, Meynadier J et al. The treatment of 45 patients with cutaneous T-cell lymphoma with low doses of interferon-alpha 2a and etretinate. Br J Dermatol 1991; 125: 456-9.
  37. Stadler R, Otte HG, Luger T et al. Prospective randomized multicentre clinical trial on the use of interferon alpha-2a plus acitretin versus interferon alpha-2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II. Blood 1998; 10: 3578-81.
  38. Kuzel TM, Roenigk HH Jr, Samuelson E et al. Effectiveness of interferon alfa-2a combined with phototherapy for mycosis fungoides and the Sézary syndrome. J Clin Oncol 1995; 13: 257-63.
  39. Rook AH, Wood GS, Yoo EK et al. Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses. Blood 1999; 94: 902-8.
  40. Kaplan EH, Rosen ST, Norris DB et al. Phase II study of recombinant interferon gamma for treatment of cutaneous T-cell lymphoma. J Nat Cancer Inst 1990; 82: 208-12.
  41. Cooper DL, Braverman IM, Sarris AH et al. Cyclosporine treatment of refractory T-cell lymphomas. Cancer 1993; 71: 2335-41.
  42. Bunn PA Jr, Hoffman SJ, Norris D et al. Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and the Sézary syndrome). Ann Intern Med 1994; 121: 592-602.
  43. Kurzrock R, Pilat S, Duvic M. Pentostatin therapy of T-cell lymphomas with cutaneous manifestations. J Clin Oncol 1999; 17: 3117-21.
  44. Dearden C, Matutes E, Catovsky D. Pentostatin treatment of cutaneous T-cell lymphoma. Oncology 2000; 14: 37-40.
  45. Zackheim HS, Kashani-sabet M, Hwang ST. Low dose methotrexate to treat erythrodermic cutaneous T-cell lymphoma: results in twenty-nine patients. J Am Acad Dermatol 1996; 34: 626-31.
  46. Wollina U, Graefe T, Kaatz M. Pegylated doxorubicin for primary cutaneous T-cell lymphoma: a report on ten patients with follow-up. J Cancer Res Clin Oncol 2001; 127: 128-34.
  47. Zinzani PL, Baliva G, Magagnoli M et al. Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients. J Clin Oncol 2000; 18: 2603-6.
  48. Olavarria E, Child F, Woolford A et al. T-cell depletion and autologous stem cell transplantation in the management of tumour stage mycosis fungoides with peripheral blood involvement. Br J Haematol 2001; 114: 624-31.
  49. Burt RK, Guitart J, Traynor A et al. Allogeneic hematopoietic stem cell transplantation for advanced mycosis fungoides: evidence of a graft-versus-tumour effect. Bone Marrow Transplant 2000; 25: 111-13.
  50. Molina A, Nademanee A, Arber DA, Forman SJ. Remission of refractory Sézary syndrome after bone marrow transplantation from a matched unrelated donor. Biol Blood Marrow Transplant 1999; 5: 400-4.
  51. Knox S, Hoppe RT, Maloney D et al. Treatment of cutaneous T-cell lymphoma with chimeric anti-CD4 monoclonal antibody. Blood 1996; 87: 893-9.
  52. Foss FM, Raubitscheck A, Mulshine JL et al. Phase I study of the pharmacokinetics of a radioimmunoconjugate, 90Y-T101, in patients with CD5-expressing leukaemia and lymphoma. Clin Cancer Res 1998; 4: 2691-700.
  53. Lundin J, Osterborg A, Brittinger G et al. CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma. J Clin Oncol 1998; 16: 3257-63.
  54. Lundin J, Hagberg H, Repp R et al. Phase II study of alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) in patients with advanced mycosis fungoides. Blood 2003; 101: 4267-72.
  55. Olsen EA, Duvic M, Frankel A et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol 2001; 19: 376-88.
  56. Duvic M, Martin AG, Kim Y, Olsen E. Worldwide Bexarotene Study Group. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early stage cutaneous T-cell lymphoma. Arch Dermatol 2001; 137: 581-93.
  57. Duvic M, Hymes K, Heald P et al. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol 2001; 19: 2456-71.
  58. Edelson R, Berger C, Gasparro F et al. Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. N Engl J Med 1987; 316: 297-303.
  59. Heald P, Rook A, Perez M et al. Treatment of erythrodermic cutaneous T-cell lymphoma with extracorporeal photopheresis. J Am Acad Dermatol 1992; 27: 427-33.
  60. Fraser-Andrews E, Seed P, Whittaker S, Russell Jones R. Extracorporeal photopheresis in Sézary syndrome: no significant effect in the survival of 44 patients with a peripheral blood T-cell clone. J Arch Dermatol 1998; 134: 1001-5.
  61. Russell Jones R. Extracorporeal photopheresis in cutaneous T-cell lymphoma. Inconsistent data underline the need for randomized studies. Br J Dermatol 2000; 142: 16-21.
  62. Evans AV, Wood BP, Scarisbrick JJ et al. Extracorporeal photopheresis in Sézary syndrome: hematologic parameters as predictors of response. Blood 2001; 98: 1298-301.
  63. Bekkenk MW, van Geelen FA, van Voorst Vader PC et al. Primary and secondary cutaneous CD30+ lymphoproliferative disorders: a report from the Dutch cutaneous lymphoma group on the long term follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood 2000; 95: 3653-61.
  64. Vonderheid EC, Sajjadian A, Kadin ME. Methotrexate is effective for lymphomatoid papulosis and other primary cutaneous CD30-positive lymphoproliferative disorders. J Am Acad Dermatol 1996; 34: 470-81.
  65. Van Doorn R, Scheffer E, Willemze R. Follicular mycosis fungoides, a distinct disease entity with or without associated follicular mucinosis. Arch Dermatol 2002; 138: 191-8.
  66. Griffiths CEM. The British Association of Dermatologists guidelines for the management of skin disease. Br J Dermatol 1999; 141: 396-7.
  67. Cox NH, Williams HC. The British Association of Dermatologists Therapeutic Guidelines: can we AGREE? Br J Dermatol 2003; 148: 621-5.